PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29335342-6	2018	All TNFi were significantly better than placebo in reducing BASDAI and BASFI at 12 weeks and 24 weeks; all but certolizumab pegol (CZP) were statistically better than placebo in reducing CRP at 12 weeks; all but CZP and infliximab-dyyb (IFX biosimilar) were significantly better than placebo in reducing CRP at 24 weeks.	Certolizumab Pegol	111-129	C-reactive protein	Homo sapiens	187-190	
34715908-2	2021	This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP).	Certolizumab Pegol	307-325	C-reactive protein	Homo sapiens	132-150	
34715908-2	2021	This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP).	Certolizumab Pegol	307-325	C-reactive protein	Homo sapiens	152-155	
34715908-2	2021	This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP).	Certolizumab Pegol	327-330	C-reactive protein	Homo sapiens	132-150	
34715908-2	2021	This analysis aims to identify whether any baseline characteristics or Week 12 clinical outcomes in nr-axSpA patients with elevated C-reactive protein (CRP) and/or sacroiliitis on magnetic resonance imaging (MRI) enrolled in the C-axSpAnd study are predictive of achieving clinical response after 1 year of certolizumab pegol (CZP).	Certolizumab Pegol	327-330	C-reactive protein	Homo sapiens	152-155	
35296532-1	2022	BACKGROUND: 52-week results from C-axSpAnd demonstrated the safety and efficacy of certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (sacroiliitis on MRI and/or elevated C-reactive protein levels).	Certolizumab Pegol	83-101	C-reactive protein	Homo sapiens	257-275	
31498074-10	2020	Predictors of poor certolizumab retention were: Current or ex-smoker [HR 1.11 (0.70-1.76), p=0.65], high CRP levels [HR 0.72 (0.45-1.16), p=0.18], biologic-naive [HR 0.81 (0.49-1.32), p=0.39] and good BASDAI50 response at first control visit [HR 0.54 (0.30-0.96), p=0.04].	Certolizumab Pegol	19-31	C-reactive protein	Homo sapiens	105-108	
29335342-6	2018	All TNFi were significantly better than placebo in reducing BASDAI and BASFI at 12 weeks and 24 weeks; all but certolizumab pegol (CZP) were statistically better than placebo in reducing CRP at 12 weeks; all but CZP and infliximab-dyyb (IFX biosimilar) were significantly better than placebo in reducing CRP at 24 weeks.	Certolizumab Pegol	131-134	C-reactive protein	Homo sapiens	187-190	
23942869-11	2014	Multiple post hoc analyses demonstrated that CZP inhibited radiographic progression compared with placebo, particularly in patients with high baseline mTSS and C-reactive protein levels.	Certolizumab Pegol	45-48	C-reactive protein	Homo sapiens	160-178	
29159893-6	2018	RESULTS: CZP concentrations at weeks 2, 4 and 6 were higher in patients with clinical response, remission, CRP <= 5 mg/L or FC <= 250 mug/g at week 6 than without.	Certolizumab Pegol	9-12	C-reactive protein	Homo sapiens	107-110	
24184736-10	2014	There was a significant inverse relationship between plasma concentrations of CZP and baseline levels of C-reactive protein and body weight (P = .0014 and P = .0373, respectively).	Certolizumab Pegol	78-81	C-reactive protein	Homo sapiens	105-123	
19180261-4	2008	Inflammatory markers such as C-reactive protein (CRP) also decrease after administration of certolizumab pegol.	Certolizumab Pegol	92-110	C-reactive protein	Homo sapiens	29-47	
21642014-9	2011	There were significantly greater rates of clinical remission at week 6 for CZP in patients with increased concentrations of C-reactive protein (>=5 mg/L) at entry.	Certolizumab Pegol	75-78	C-reactive protein	Homo sapiens	124-142	
21642014-12	2011	Significant differences between CZP and placebo were observed in patients who had increased concentrations of C-reactive protein when the study began.	Certolizumab Pegol	32-35	C-reactive protein	Homo sapiens	110-128	
19180261-4	2008	Inflammatory markers such as C-reactive protein (CRP) also decrease after administration of certolizumab pegol.	Certolizumab Pegol	92-110	C-reactive protein	Homo sapiens	49-52	
17634458-5	2007	RESULTS: Among patients with a baseline CRP level of at least 10 mg per liter, 37% of patients in the certolizumab group had a response at week 6, as compared with 26% in the placebo group (P=0.04).	Certolizumab Pegol	102-114	C-reactive protein	Homo sapiens	40-43	
17516714-3	2007	Subcutaneous certolizumab pegol 400mg once every 4 weeks (with an additional 400mg dose at week 2) was effective as induction and maintenance therapy in patients with moderate to severe Crohn"s disease in whom baseline serum C-reactive protein levels were >/=10 mg/L, according to data from two well designed, randomized phase III trials.	Certolizumab Pegol	13-31	C-reactive protein	Homo sapiens	225-243	
16143120-6	2005	Patients with baseline C-reactive protein levels of 10 mg/L or greater (n = 119) showed clearer separation between active treatment and placebo (week 12 clinical response: certolizumab 400 mg, 53.1%; placebo, 17.9%; P = .005; post hoc analysis) owing to a lower placebo response rate than patients with C-reactive protein levels of less than 10 mg/L.	Certolizumab Pegol	172-184	C-reactive protein	Homo sapiens	23-41	
16143120-9	2005	High placebo response rates in the large patient subgroup with low C-reactive protein levels may have obscured statistical separation between certolizumab and placebo.	Certolizumab Pegol	142-154	C-reactive protein	Homo sapiens	67-85